News & Updates

ADT in prostate cancer: Should docetaxel be added?

02 Mar 2020 by

While combining docetaxel with androgen deprivation therapy (ADT) is known to improve survival for advanced prostate cancer, its role in the setting of adjuvant treatment given after radical radiotherapy plus ADT for the treatment of intermediate- and high-risk prostate cancer was proven otherwise — both in terms of biochemical disease-free survival (BDFS) and quality of life (QoL), according to the SPCG*-13 trial presented at the 2020 Genitourinary Cancer Symposium (GUCS).

ADT in prostate cancer: Should docetaxel be added?

02 Mar 2020

Apalutamide plus ADT improves PFS2 in mCSPC

29 Feb 2020 by

The addition of apalutamide, a novel androgen receptor inhibitor, to androgen deprivation therapy (ADT) reduced the risk of progression while on first subsequent therapy or death (PFS2) in men with metastatic castration-sensitive prostate cancer (mCSPC), according to exploratory analysis of the phase III TITAN* trial.

Apalutamide plus ADT improves PFS2 in mCSPC

29 Feb 2020

Is discordant antibiotic use appropriate for third-generation cephalosporin-resistant UTIs?

28 Feb 2020

Most children treated with discordant antibiotics for third-generation cephalosporin-resistant urinary tract infections (UTIs) may experience initial clinical improvement, with only a few requiring escalation of care, according to a study. This highlights the aptness of using current narrow-spectrum empiric therapy regimens while awaiting final urine culture results.

Is discordant antibiotic use appropriate for third-generation cephalosporin-resistant UTIs?

28 Feb 2020

Improved pain response with cabazitaxel vs ARTA in mCRPC

27 Feb 2020 by

In addition to extending survival, cabazitaxel also improves pain and quality of life (QoL) compared with abiraterone or enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC), results from the phase III CARD* trial showed.

Improved pain response with cabazitaxel vs ARTA in mCRPC

27 Feb 2020

$Long-term follow up confirms noninferiority of moderate hypofractionation to conventional RT for prostate cancer$

Long-term follow up confirms noninferiority of moderate hypofractionation to conventional RT for prostate cancer

25 Feb 2020 by

A moderately hypofractionated radiotherapy (RT) dose schedule was noninferior to conventional RT, according to the 8-year outcomes from the CHHiP* trial presented at ASCO GU 2020.

Long-term follow up confirms noninferiority of moderate hypofractionation to conventional RT for prostate cancer

25 Feb 2020

MDR UTIs in pregnancy prone to progressing to pyelonephritis

22 Feb 2020 by

Pregnant women with urinary tract infections (UTIs) caused by multidrug-resistant (MDR) bacteria may be at increased risk of developing pyelonephritis, according to a single-centre, retrospective study presented at SMFM 2020.

MDR UTIs in pregnancy prone to progressing to pyelonephritis

22 Feb 2020

Frequent voiding at night ups risk of death

17 Feb 2020 by

Nocturia, or waking from sleep two or more times at night to void, appears to slightly increase the risk of mortality, results of a systematic review and meta-analysis have shown.

Frequent voiding at night ups risk of death

17 Feb 2020

Metabolic acidosis tied to improvement of urinary continence after neobladder creation

15 Feb 2020

An association exists between the development of metabolic acidosis following ileal neobladder construction and continuous improvement of urinary continence in the early recovery period, reveals a recent study.

Metabolic acidosis tied to improvement of urinary continence after neobladder creation

15 Feb 2020

Fosfomycin trometamol on par with other antibiotics for treatment of acute uncomplicated cystitis

14 Feb 2020

The clinical and microbiological effectiveness of a single dose of oral fosfomycin trometamol is comparable to that of comparator antibiotics, as is safety, in women with confirmed or suspected acute uncomplicated cystitis, a recent study has shown. Use of fosfomycin trometamol is also associated with high patient compliance.

Fosfomycin trometamol on par with other antibiotics for treatment of acute uncomplicated cystitis

14 Feb 2020

Eating greens yields no benefit for prostate cancer

14 Feb 2020 by

Increasing vegetable consumption did not significantly reduce the risk of prostate cancer progression in men with early-stage disease on active surveillance, the MEAL* trial shows, which contradicts clinical guidelines recommending a vegetable-rich diet in this patient setting.

Eating greens yields no benefit for prostate cancer

14 Feb 2020

News & Updates

Filter by Specialty:

Specialty:

ADT in prostate cancer: Should docetaxel be added?

ADT in prostate cancer: Should docetaxel be added?

Apalutamide plus ADT improves PFS2 in mCSPC

Apalutamide plus ADT improves PFS2 in mCSPC

Is discordant antibiotic use appropriate for third-generation cephalosporin-resistant UTIs?

Is discordant antibiotic use appropriate for third-generation cephalosporin-resistant UTIs?

Improved pain response with cabazitaxel vs ARTA in mCRPC

Improved pain response with cabazitaxel vs ARTA in mCRPC

Long-term follow up confirms noninferiority of moderate hypofractionation to conventional RT for prostate cancer

Long-term follow up confirms noninferiority of moderate hypofractionation to conventional RT for prostate cancer

MDR UTIs in pregnancy prone to progressing to pyelonephritis

MDR UTIs in pregnancy prone to progressing to pyelonephritis

Frequent voiding at night ups risk of death

Frequent voiding at night ups risk of death

Metabolic acidosis tied to improvement of urinary continence after neobladder creation

Metabolic acidosis tied to improvement of urinary continence after neobladder creation

Fosfomycin trometamol on par with other antibiotics for treatment of acute uncomplicated cystitis

Fosfomycin trometamol on par with other antibiotics for treatment of acute uncomplicated cystitis

Eating greens yields no benefit for prostate cancer

Eating greens yields no benefit for prostate cancer